Our Journey
Pioneering RNA Therapeutics
Dexoligo Therapeutics was founded in 2021 by Dexcel Pharma, Israel’s largest privately held pharmaceutical company, with the vision of establishing an impactful and innovative RNA therapeutics endeavor. The Dexcel group is a leading investor in cutting-edge scientific ventures, and has been involved in the formation of numerous pioneering biomedical companies, such as Roivant Sciences, Clexio Biosciences, Kriya Therapeutics, and more.
RNA Therapeutics Vision
With the vision of establishing an impactful and innovative RNA therapeutics endeavor. The Dexcel group is a leading investor in cutting-edge scientific ventures, and has been involved in the formation of numerous pioneering biomedical companies, such as Roivant Sciences, Clexio Biosciences, Kriya Therapeutics, and more.
Our Team
Shay Sela
PhD
Head of Dexoligo Therapeutics
Elena Feinstein
MD, PhD
Chief Scientist
Avital Laxer
PhD
Head of CMC
Emmanuel Weyl
M.Sc, MBA
Head of Business Development
Nadav Marbach-Bar
PhD
Head of Discovery
Noa Madar-Balakirski
PhD
Head of Preclinical Development
Osnat Penn
PhD
Head of Computational Biology
Tamar Shiloach
PhD
Head of Translational Sciences
Maya Shemesh
PhD
Project Leader
Shirlly Toma
BA English Literature
BA Law
Administration Manager
Eli Kopel
PhD
Senior Computational Biologist
Juman Jubran
PhD
Computational Biologist
Lian Narunsky Haziza
PhD
Senior Translational Scientist
Yael Garbian
PhD
Head of Lab
Gal Yosef Goldshtein
PhD
Senior Scientist
Lena Paker Krush
M.Sc.
Scientist
